Lung Cancer
A PHASE 3 MULTICENTER DOUBLE-BLIND RANDOMIZED STUDY OF TALETRECTINIB VERSUS PLACEBO IN PATIENTS WITH ROS1-FUSION POSITIVE STAGE IB-IIIA NON-SMALL CELL LUNG CANCER WHO HAVE UNDERGONE COMPLETE TUMOR RESECTION (AB-106-G319)
- Details
ClinicalTrials.gov ID:
NCT07154706
Diagnosis Type:
NA
USOR Number:
- Address
,
P: